June 6, 2018
Study: Medical device tax hurts investment in R&D
Editor's Note:
This study from Iowa State University shows companies have cut funding for research and development (R&D) in response to the medical device tax imposed by the Affordable Care Act.
Since 2013, the 2.3% excise tax has significantly reduced:
- R&D investment by $34 million
- Sales revenue by $188 million
- Gross margins by $375 million
- Earnings by $68 million.
The study, which is the first to look at the actual cost of the tax on manufacturers, found it also affected operating and marketing costs.
Free Daily News
- Take the OR Manager Career/Salary Survey, help shape the future of perioperative leadership
- Virtual care, tech-enabled roles reshape nursing as leaders diverge on care redesign priorities
- As healthcare faces skyrocketing cyberattacks, surgeons are urged to lead frontline defense
- Study shows WHO surgical checklist boosts safety, but compliance gaps risk patient outcomes
- Kentucky Derby, SPD race: Leadership lessons energized SPD professionals at HSPA 2025
- Continuum-based protocol offers new strategy for preventing PONV after thyroidectomy
- Pembrolizumab sets new standard in advanced head and neck cancer surgery, trial shows
- Subarachnoid spinal anesthesia offers safe, effective option for high-risk obstetric patients
- Same-day discharge after catheter ablation gains backing from top cardiology societies
- Tenet, HCA post strong Q1 results, but caution looms over policy uncertainty, outpatient trends
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement